 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
4 News |  |
- || Potaba (potassium p-aminobenzoate) / Cheplapharm
Review, Journal: Analysis of evidence on nutraceutical interventions for Peyronie's disease: a guideline-based critical review. (Pubmed Central) - May 29, 2024
This critical comparative analysis of the most recent guidelines produced by the leading scientific societies highlights some inconsistencies in the recommendations on nutraceutical intervention for PD, even within a background of overall ineffectiveness of this treatment approach.
- Potaba (potassium p-aminobenzoate) / Cheplapharm
What do patients with induratio penis plastica expect from conservative and surgical therapy? Results of a prospective study from a high-volume center (#21) (Carl Zeiss Hall on the right) - May 29, 2022 - Abstract #NORDKONGRESS2022NORDKONGRESS_57;
IPP patients expect fewer positive but also fewer negative effects from conservative therapy than from surgical therapy. The evaluation of expectations is important for the treatment of IPP patients in order to define realistic expectations and therapy goals.
- | Intron A (interferon α-2b) / Merck (MSD), Biogen
Journal: Non-surgical management of Peyronie's disease: State of current knowledge (Pubmed Central) - May 12, 2021
Multiple therapeutic strategies exist for the management of the Peyronie's disease, but they lack evidence based data. Further randomized clinical trials are needed to evaluate the current practices and to study more efficient treatments.